Products Categories
CAS No.: | 70052-12-9 |
---|---|
Name: | DFMO |
Article Data: | 5 |
Molecular Structure: | |
Formula: | C6H12F2N2O2 |
Molecular Weight: | 182.17 |
Synonyms: | 2-(Difluoromethyl)-DL-ornithine;2-(Difluoromethyl)ornithine;DFMO;DFMO (growth regulator);DL-2-(Difluoromethyl)ornithine;DL-a-(Difluoromethyl)ornithine;Elfornithine;Ornidyl;a,d-Diamino-a-(difluoromethyl)valericacid;a-(Difluoromethyl)-DL-ornithine;a-(Difluoromethyl)ornithine; |
Density: | 1.293g/cm3 |
Melting Point: | 138 °C |
Boiling Point: | 347 °C at 760 mmHg |
Flash Point: | 163.7 °C |
PSA: | 89.34000 |
LogP: | 1.17310 |
IUPAC Name: 2,5-diamino-2-(difluoromethyl)pentanoic acid
Molecular Formula: C6H12F2N2O2
Molar mass: 182.1685 g/mol
EINECS: 222-760-4
Density: 1.293 g/cm3
Flash Point: 163.7 °C
Index of Refraction: 1.462
Boiling Point: 347 °C at 760 mmHg
Vapour Pressure: 9.72E-06 mmHg at 25°C
Storage temp: Store at 0 °C
Solubility: H2O >10 mg/mL, soluble
Form: Solid
Color: White
Product categories: facial hair remover
Structure of Eflornithine (CAS NO.70052-12-9):
XLogP3-AA: -2.9
H-Bond Donor: 3
H-Bond Acceptor: 6
IUPAC Name: 2,5-Diamino-2-(difluoromethyl)pentanoic acid
Canonical SMILES: C(CC(C(F)F)(C(=O)O)N)CN
InChI: InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,
12)
InChIKey: VLCYCQAOQCDTCN-UHFFFAOYSA-N
Eflornithine (CAS NO.70052-12-9) is a drug manufactured by Sanofi-Aventis that has various uses. A recent study (reported 2008 ) conducted by UC Irvine researchers indicates that, when combined with sulindac , Eflornithine significantly reduces the risk of recurring colorectal polyps. It was initially developed for cancer treatment, but, while having little use in treating malignancies. In the United States it is known by the brand name Ornidyl.
Eflornithine (CAS NO.70052-12-9), its production was halted by its manufacturer, Aventis, in 1995 because the company did not consider it a profitable drug. In 2001, after lobbying at the WHO World Health Organization by Médecins Sans Frontières ("Doctors Without Borders"), the manufacturer resumed production of eflornithine, melarsoprol, and pentamidine in sufficient amounts to cover existing needs. As of September 2005, the World Health Organization reports that the India Institute of Chemical Technology in Hyderabad, India and ILEX Oncology in Texas, United States are both working on new ways of making eflornithine more cheaply.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | intravenous | 9084mg/kg/2W- (9084mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA | Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987. |
man | TDLo | oral | 800mg/kg/4D-I (800mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA | Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987. |
women | LDLo | intravenous | 67mg/kg/40M-C (67mg/kg) | CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: PULSE RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Annals of Internal Medicine. Vol. 105, Pg. 141, 1986. |
Human systemic effects by intravenous route: cardiomyopathy, pulse rate decrease, fall in blood pressure. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of F− and NOx.
Eflornithine , its cas register number is 70052-12-9. It also can be called Difluoromethylornithine ; Ornidyl ; Ornithine, 2-(difluoromethyl)- and a-Difluoromethylornithine .